# NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

> Contract award record from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Contract winner: Biogen
- Award value: £986,282,758
- Tender value: £4,108,145,000
- Award date: 1 July 2025
- Published: 29 July 2025
- Contract start: 1 September 2025
- Contract end: 31 August 2027
- Stage: awarded
- Procurement category: goods
- Notice ID: cc644418-f584-45db-bf35-771baf03bc48-856590
- OCID: ocds-b5fd17-04aa1520-7ead-4f1f-bebb-422062580323

## Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East\. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend \(at the Authority's discretion\) for a period or periods up to a total of 24 months\. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE\. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend \(at the Authority's discretion\) for a period or periods up to a total of 12 months\.

## Related contract awards

- [Slack Enterprise Plus Licences 2026/27](/contracts/ocds-b5fd17-a5a9a52b-aebd-4eb2-9385-b1f0defaa81e): NHS England
- [Smartcards Service](/contracts/ocds-b5fd17-7ab50116-be00-4ea2-910f-ed237bdcdff6): NHS England
- [2025/NCA\.Spinal Independent Patient Safety Investigation](/contracts/ocds-b5fd17-377821fc-dde1-4f7d-8504-7b344ee7707f): NHS England
- [NHS Framework Agreement for the supply of Ranibizumab for the NHS in England](/contracts/ocds-b5fd17-e7c59f94-d69d-41c8-bee3-a3312c4c93fd): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/cc644418-f584-45db-bf35-771baf03bc48-856590)